CRISPR screen reveals modifiers of rAAV production including known rAAV infection genes playing an unexpected role in vector production
Recombinant adeno-associated virus (rAAV) vectors are an effective and well-established tool in the growing gene therapy field, with five U.S. Food and Drug Administration-approved AAV-mediated gene therapies already on the market and numerous more in clinical trials. However, manufacturing rAAV vec...
| Հիմնական հեղինակներ: | , , , , |
|---|---|
| Ձևաչափ: | Հոդված |
| Լեզու: | English |
| Հրապարակվել է: |
Elsevier
2025-03-01
|
| Շարք: | Molecular Therapy: Methods & Clinical Development |
| Խորագրեր: | |
| Առցանց հասանելիություն: | http://www.sciencedirect.com/science/article/pii/S2329050125000038 |